Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118917 | 1.00 | KMT2A (0.51) | KMT2ACES2CES1HSD17B14L3MBTL1 | |
| SCHEMBL8710005 | 0.82 | KMT2A (0.58) | KMT2ACES2CES1HSD17B14L3MBTL1 | |
| SCHEMBL30118935 | 0.82 | KMT2A (0.58) | KMT2ACES2CES1HSD17B14L3MBTL1 | |
| SCHEMBL22426344 | 0.81 | P2RX1 (0.40) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL28255112 | 0.80 | KDM4C (0.47) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL22406359 | 0.79 | P2RX7 (0.44) | KMT2ACES1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL22406337 | 0.78 | RAB9A (0.60) | KMT2ACES2CES1ALDH1A1RAB9A | |
| SCHEMBL30118904 | 0.78 | RAB9A (0.60) | KMT2ACES2CES1ALDH1A1RAB9A | |
| SCHEMBL31369148 | 0.75 | KMT2A (0.75) | KMT2ACES2CES1HSD17B14L3MBTL1 | |
| SCHEMBL87791 | 0.75 | KMT2A (0.75) | KMT2ACES2CES1HSD17B14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| EP-3938364-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| WO-2020186291-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020186291-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-24 | — | — | WO | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | SNCA, PARK7, HTT | KMT2A 654/4885CES2 4454/4885CES1 4806/4885 |
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | KMT2A 730/4885CES2 3806/4885CES1 4780/4885 |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | SNCA, HTT, PARK7 | KMT2A 555/4885CES2 4431/4885CES1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.